Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

AI can now identify atrial fibrillation through sinus rhythm.

Hendriks JML, Fabritz L.

Lancet. 2019 Aug 1. pii: S0140-6736(19)31719-2. doi: 10.1016/S0140-6736(19)31719-2. [Epub ahead of print] No abstract available.

PMID:
31378397
2.

High-Throughput Analysis of Optical Mapping Data Using ElectroMap.

O'Shea C, Holmes AP, Yu TY, Winter J, Wells SP, Parker BA, Fobian D, Johnson DM, Correia J, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D.

J Vis Exp. 2019 Jun 4;(148). doi: 10.3791/59663.

PMID:
31233017
3.

The Biomarkers NT-proBNP and CA-125 are Elevated in Patients with Idiopathic Atrial Fibrillation.

Dudink EA, Weijs B, Tull S, Luermans JG, Fabritz L, Chua W, Rienstra M, Gelder ICV, Schotten U, Kirchhof P, Crijns HJ.

J Atr Fibrillation. 2018 Dec 31;11(4):2058. doi: 10.4022/jafib.2058. eCollection 2018 Dec.

4.

Development and external validation of predictive models for prevalent and recurrent atrial fibrillation: a protocol for the analysis of the CATCH ME combined dataset.

Chua W, Easter CL, Guasch E, Sitch A, Casadei B, Crijns HJGM, Haase D, Hatem S, Kääb S, Mont L, Schotten U, Sinner MF, Hemming K, Deeks JJ, Kirchhof P, Fabritz L.

BMC Cardiovasc Disord. 2019 May 21;19(1):120. doi: 10.1186/s12872-019-1105-4.

5.

Cardiac Optogenetics and Optical Mapping - Overcoming Spectral Congestion in All-Optical Cardiac Electrophysiology.

O'Shea C, Holmes AP, Winter J, Correia J, Ou X, Dong R, He S, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D.

Front Physiol. 2019 Mar 7;10:182. doi: 10.3389/fphys.2019.00182. eCollection 2019. Review.

6.

SMART About Watches: We Need Technical and Biological Validation of Atrial Fibrillation Screening.

Kalla M, Fabritz L, Kirchhof P.

JACC Clin Electrophysiol. 2019 Feb;5(2):209-211. doi: 10.1016/j.jacep.2018.11.018. No abstract available.

PMID:
30784692
7.

ElectroMap: High-throughput open-source software for analysis and mapping of cardiac electrophysiology.

O'Shea C, Holmes AP, Yu TY, Winter J, Wells SP, Correia J, Boukens BJ, De Groot JR, Chu GS, Li X, Ng GA, Kirchhof P, Fabritz L, Rajpoot K, Pavlovic D.

Sci Rep. 2019 Feb 4;9(1):1389. doi: 10.1038/s41598-018-38263-2.

8.

Data-driven discovery and validation of circulating blood-based biomarkers associated with prevalent atrial fibrillation.

Chua W, Purmah Y, Cardoso VR, Gkoutos GV, Tull SP, Neculau G, Thomas MR, Kotecha D, Lip GYH, Kirchhof P, Fabritz L.

Eur Heart J. 2019 Apr 21;40(16):1268-1276. doi: 10.1093/eurheartj/ehy815.

9.

German Cardiac Society Working Group on Cellular Electrophysiology state-of-the-art paper: impact of molecular mechanisms on clinical arrhythmia management.

Thomas D, Christ T, Fabritz L, Goette A, Hammwöhner M, Heijman J, Kockskämper J, Linz D, Odening KE, Schweizer PA, Wakili R, Voigt N.

Clin Res Cardiol. 2019 Jun;108(6):577-599. doi: 10.1007/s00392-018-1377-1. Epub 2018 Oct 10. Review.

PMID:
30306295
10.

The VAMP-associated protein VAPB is required for cardiac and neuronal pacemaker channel function.

Silbernagel N, Walecki M, Schäfer MK, Kessler M, Zobeiri M, Rinné S, Kiper AK, Komadowski MA, Vowinkel KS, Wemhöner K, Fortmüller L, Schewe M, Dolga AM, Scekic-Zahirovic J, Matschke LA, Culmsee C, Baukrowitz T, Monassier L, Ullrich ND, Dupuis L, Just S, Budde T, Fabritz L, Decher N.

FASEB J. 2018 Nov;32(11):6159-6173. doi: 10.1096/fj.201800246R. Epub 2018 Jun 7.

11.

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy.

Pavlovic D, Kirchhof P, Fabritz L.

Eur Heart J. 2018 Aug 21;39(32):2997-2999. doi: 10.1093/eurheartj/ehy018. No abstract available.

12.

Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors.

Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, Müller FU, Stümpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J.

Front Pharmacol. 2018 Jan 22;9:13. doi: 10.3389/fphar.2018.00013. eCollection 2018.

13.

Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference.

Kotecha D, Breithardt G, Camm AJ, Lip GYH, Schotten U, Ahlsson A, Arnar D, Atar D, Auricchio A, Bax J, Benussi S, Blomstrom-Lundqvist C, Borggrefe M, Boriani G, Brandes A, Calkins H, Casadei B, Castellá M, Chua W, Crijns H, Dobrev D, Fabritz L, Feuring M, Freedman B, Gerth A, Goette A, Guasch E, Haase D, Hatem S, Haeusler KG, Heidbuchel H, Hendriks J, Hunter C, Kääb S, Kespohl S, Landmesser U, Lane DA, Lewalter T, Mont L, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Pison L, Potpara T, Ravens U, Richard-Lordereau I, Rienstra M, Savelieva I, Schnabel R, Sinner MF, Sommer P, Themistoclakis S, Van Gelder IC, Vardas PE, Verma A, Wakili R, Weber E, Werring D, Willems S, Ziegler A, Hindricks G, Kirchhof P.

Europace. 2018 Mar 1;20(3):395-407. doi: 10.1093/europace/eux318.

14.

European Society of Cardiology smartphone and tablet applications for patients with atrial fibrillation and their health care providers.

Kotecha D, Chua WWL, Fabritz L, Hendriks J, Casadei B, Schotten U, Vardas P, Heidbuchel H, Dean V, Kirchhof P; European Society of Cardiology (ESC) Atrial Fibrillation Guidelines Taskforce, the CATCH ME consortium and the European Heart Rhythm Association (EHRA).

Europace. 2018 Feb 1;20(2):225-233. doi: 10.1093/europace/eux299. Review.

15.

Mast Cells Granular Contents Are Crucial for Deep Vein Thrombosis in Mice.

Ponomaryov T, Payne H, Fabritz L, Wagner DD, Brill A.

Circ Res. 2017 Sep 29;121(8):941-950. doi: 10.1161/CIRCRESAHA.117.311185. Epub 2017 Jul 24.

16.

PITX2-dependent gene regulation in atrial fibrillation and rhythm control.

Syeda F, Kirchhof P, Fabritz L.

J Physiol. 2017 Jun 15;595(12):4019-4026. doi: 10.1113/JP273123. Epub 2017 Apr 25. Review.

17.

Anterior T-Wave Inversion Does Not Convey Short-Term Sudden Death Risk: Inverted Is the New Normal.

Kirchhof P, Fabritz L.

J Am Coll Cardiol. 2017 Jan 3;69(1):10-12. doi: 10.1016/j.jacc.2016.11.011. No abstract available.

18.

PITX2 Modulates Atrial Membrane Potential and the Antiarrhythmic Effects of Sodium-Channel Blockers.

Syeda F, Holmes AP, Yu TY, Tull S, Kuhlmann SM, Pavlovic D, Betney D, Riley G, Kucera JP, Jousset F, de Groot JR, Rohr S, Brown NA, Fabritz L, Kirchhof P.

J Am Coll Cardiol. 2016 Oct 25;68(17):1881-1894. doi: 10.1016/j.jacc.2016.07.766.

19.

A Regional Reduction in Ito and IKACh in the Murine Posterior Left Atrial Myocardium Is Associated with Action Potential Prolongation and Increased Ectopic Activity.

Holmes AP, Yu TY, Tull S, Syeda F, Kuhlmann SM, O'Brien SM, Patel P, Brain KL, Pavlovic D, Brown NA, Fabritz L, Kirchhof P.

PLoS One. 2016 May 5;11(5):e0154077. doi: 10.1371/journal.pone.0154077. eCollection 2016.

20.

Can biomarkers balance stroke and bleeding risk?

Kirchhof P, Fabritz L.

Lancet. 2016 Jun 4;387(10035):2266-2268. doi: 10.1016/S0140-6736(16)30121-0. Epub 2016 Apr 4. No abstract available.

PMID:
27056737
21.

Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin personalized prevention and treatment.

Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, Hidden-Lucet F, Kääb S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P.

Nat Rev Cardiol. 2016 Apr;13(4):230-7. doi: 10.1038/nrcardio.2015.194. Epub 2015 Dec 24. Review.

PMID:
26701216
22.

The power of P in the elderly: Small biphasic wave, big impact.

Fabritz L.

Heart Rhythm. 2016 Mar;13(3):652-3. doi: 10.1016/j.hrthm.2015.11.027. Epub 2015 Nov 18. No abstract available.

23.

A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.

Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S, Ziegler A, Lip GY, Camm AJ.

Europace. 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. Epub 2015 Oct 18. Review.

PMID:
26481149
24.

The European Network for Translational Research in Atrial Fibrillation (EUTRAF): objectives and initial results.

Schotten U, Hatem S, Ravens U, Jaïs P, Müller FU, Goette A, Rohr S, Antoons G, Pieske B, Scherr D, Oto A, Casadei B, Verheule S, Cartlidge D, Steinmeyer K, Götsche T, Dobrev D, Kockskämper J, Lendeckel U, Fabritz L, Kirchhof P, Camm AJ; EUTRAF investigators.

Europace. 2015 Oct;17(10):1457-66. doi: 10.1093/europace/euv252. Epub 2015 Sep 12. Review.

PMID:
26364316
25.

Late Sodium Current in Human Atrial Cardiomyocytes from Patients in Sinus Rhythm and Atrial Fibrillation.

Poulet C, Wettwer E, Grunnet M, Jespersen T, Fabritz L, Matschke K, Knaut M, Ravens U.

PLoS One. 2015 Jun 29;10(6):e0131432. doi: 10.1371/journal.pone.0131432. eCollection 2015.

26.

Universal cardiac induction of human pluripotent stem cells in two and three-dimensional formats: implications for in vitro maturation.

Zhang M, Schulte JS, Heinick A, Piccini I, Rao J, Quaranta R, Zeuschner D, Malan D, Kim KP, Röpke A, Sasse P, Araúzo-Bravo M, Seebohm G, Schöler H, Fabritz L, Kirchhof P, Müller FU, Greber B.

Stem Cells. 2015 May;33(5):1456-69. doi: 10.1002/stem.1964.

27.

First report on an inotropic peptide activating tetrodotoxin-sensitive, "neuronal" sodium currents in the heart.

Kirchhof P, Tal T, Fabritz L, Klimas J, Nesher N, Schulte JS, Ehling P, Kanyshkova T, Budde T, Nikol S, Fortmueller L, Stallmeyer B, Müller FU, Schulze-Bahr E, Schmitz W, Zlotkin E, Kirchhefer U.

Circ Heart Fail. 2015 Jan;8(1):79-88. doi: 10.1161/CIRCHEARTFAILURE.113.001066. Epub 2014 Nov 25.

PMID:
25424392
28.

An automated system using spatial oversampling for optical mapping in murine atria. Development and validation with monophasic and transmembrane action potentials.

Yu TY, Syeda F, Holmes AP, Osborne B, Dehghani H, Brain KL, Kirchhof P, Fabritz L.

Prog Biophys Mol Biol. 2014 Aug;115(2-3):340-8. doi: 10.1016/j.pbiomolbio.2014.07.012. Epub 2014 Aug 15.

29.

Of hammers and screws: renin-angiotensin-aldosterone system inhibition to prevent atrial fibrillation in patients with hypertension.

Kirchhof P, Fabritz L.

Eur Heart J. 2014 May;35(18):1169-71. doi: 10.1093/eurheartj/ehu068. Epub 2014 Feb 23. No abstract available.

PMID:
24566798
30.

To the Editor--Propranolol, a β-adrenoreceptor blocker, prevents arrhythmias also by its sodium channel blocking effect.

Fabritz L, Franz MR, Carmeliet E, Kirchhof P.

Heart Rhythm. 2014 Mar;11(3):e1. doi: 10.1016/j.hrthm.2013.12.027. Epub 2013 Dec 19. No abstract available.

PMID:
24361342
31.

Selective atrial profibrotic signalling in mice and man.

Fabritz L, Kirchhof P.

Cardiovasc Res. 2013 Sep 1;99(4):592-4. doi: 10.1093/cvr/cvt188. No abstract available.

PMID:
23960088
32.

Flecainide acetate for the treatment of atrial and ventricular arrhythmias.

Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P.

Expert Opin Pharmacother. 2013 Feb;14(3):347-57. doi: 10.1517/14656566.2013.759212. Epub 2013 Jan 7. Review.

PMID:
23294160
33.

Minimally invasive closed-chest ultrasound-guided substance delivery into the pericardial space in mice.

Laakmann S, Fortmüller L, Piccini I, Grote-Wessels S, Schmitz W, Breves G, Kirchhof P, Fabritz L.

Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):227-38. doi: 10.1007/s00210-012-0815-2. Epub 2012 Dec 19.

34.

Gene construction, expression and functional testing of an inotropic peptide from the venom of the black scorpion Hottentotta judaicus.

Tekook MA, Fabritz L, Kirchhof P, König S, Müller FU, Schmitz W, Tal T, Zlotkin E, Kirchhefer U.

Toxicon. 2012 Dec 15;60(8):1415-27. doi: 10.1016/j.toxicon.2012.10.008. Epub 2012 Oct 22.

PMID:
23085191
35.

Arrhythmogenic right ventricular cardiomyopathy: an update on pathophysiology, genetics, diagnosis, and risk stratification.

Paul M, Wichter T, Fabritz L, Waltenberger J, Schulze-Bahr E, Kirchhof P.

Herzschrittmacherther Elektrophysiol. 2012 Sep;23(3):186-95. doi: 10.1007/s00399-012-0233-7. Epub 2012 Sep 26. Review.

PMID:
23011601
36.

Can preload-reducing therapy prevent disease progression in arrhythmogenic right ventricular cardiomyopathy? Experimental evidence and concept for a clinical trial.

Fabritz L, Fortmüller L, Yu TY, Paul M, Kirchhof P.

Prog Biophys Mol Biol. 2012 Oct-Nov;110(2-3):340-6. doi: 10.1016/j.pbiomolbio.2012.08.010. Epub 2012 Aug 27. Review.

PMID:
22944071
37.

An introduction to murine models of atrial fibrillation.

Riley G, Syeda F, Kirchhof P, Fabritz L.

Front Physiol. 2012 Aug 3;3:296. doi: 10.3389/fphys.2012.00296. eCollection 2012.

38.

Ventricular HCN channels decrease the repolarization reserve in the hypertrophic heart.

Hofmann F, Fabritz L, Stieber J, Schmitt J, Kirchhof P, Ludwig A, Herrmann S.

Cardiovasc Res. 2012 Aug 1;95(3):317-26. doi: 10.1093/cvr/cvs184. Epub 2012 May 31.

PMID:
22652004
39.

Modulation of SR Ca2+ release by the triadin-to-calsequestrin ratio in ventricular myocytes.

Kučerová D, Baba HA, Bokník P, Fabritz L, Heinick A, Mát'uš M, Müller FU, Neumann J, Schmitz W, Kirchhefer U.

Am J Physiol Heart Circ Physiol. 2012 May 15;302(10):H2008-17. doi: 10.1152/ajpheart.00457.2011. Epub 2012 Mar 16.

40.

Popeye domain containing proteins are essential for stress-mediated modulation of cardiac pacemaking in mice.

Froese A, Breher SS, Waldeyer C, Schindler RF, Nikolaev VO, Rinné S, Wischmeyer E, Schlueter J, Becher J, Simrick S, Vauti F, Kuhtz J, Meister P, Kreissl S, Torlopp A, Liebig SK, Laakmann S, Müller TD, Neumann J, Stieber J, Ludwig A, Maier SK, Decher N, Arnold HH, Kirchhof P, Fabritz L, Brand T.

J Clin Invest. 2012 Mar;122(3):1119-30. doi: 10.1172/JCI59410. Epub 2012 Feb 22.

41.

Postrepolarization refractoriness: a mechanism in need for a molecule?

Kirchhof P, Fabritz L.

Heart Rhythm. 2012 Jun;9(6):983-4. doi: 10.1016/j.hrthm.2012.02.012. Epub 2012 Feb 12. No abstract available.

PMID:
22334152
42.

Proarrhythmia in a non-failing murine model of cardiac-specific Na+/Ca 2+ exchanger overexpression: whole heart and cellular mechanisms.

Pott C, Muszynski A, Ruhe M, Bögeholz N, Schulte JS, Milberg P, Mönnig G, Fabritz L, Goldhaber JI, Breithardt G, Schmitz W, Philipson KD, Eckardt L, Kirchhof P, Müller FU.

Basic Res Cardiol. 2012 Mar;107(2):247. doi: 10.1007/s00395-012-0247-7. Epub 2012 Feb 11.

43.

Overexpression of cAMP-response element modulator causes abnormal growth and development of the atrial myocardium resulting in a substrate for sustained atrial fibrillation in mice.

Kirchhof P, Marijon E, Fabritz L, Li N, Wang W, Wang T, Schulte K, Hanstein J, Schulte JS, Vogel M, Mougenot N, Laakmann S, Fortmueller L, Eckstein J, Verheule S, Kaese S, Staab A, Grote-Wessels S, Schotten U, Moubarak G, Wehrens XH, Schmitz W, Hatem S, Müller FU.

Int J Cardiol. 2013 Jun 20;166(2):366-74. doi: 10.1016/j.ijcard.2011.10.057. Epub 2011 Nov 16. Erratum in: Int J Cardiol. 2014 Apr 1;172(3):631.

PMID:
22093963
44.

Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue.

Kahr PC, Piccini I, Fabritz L, Greber B, Schöler H, Scheld HH, Hoffmeier A, Brown NA, Kirchhof P.

PLoS One. 2011;6(10):e26389. doi: 10.1371/journal.pone.0026389. Epub 2011 Oct 19.

45.

High-density lipoprotein shortens the ventricular action potential. A novel explanation for how statins prevent sudden arrhythmic death?

Kirchhof P, Fabritz L.

J Am Coll Cardiol. 2011 Jun 28;58(1):45-7. doi: 10.1016/j.jacc.2010.12.048. No abstract available.

46.

Can T-type calcium channels make a change of heart after myocardial infarction? Fiction or fact, and for better or for worse?

Fabritz L, Herzig S.

Cardiovasc Res. 2011 Aug 1;91(3):373-5. doi: 10.1093/cvr/cvr177. Epub 2011 Jun 17. No abstract available.

PMID:
21685207
47.

Arrhythmogenic left atrial cellular electrophysiology in a murine genetic long QT syndrome model.

Lemoine MD, Duverger JE, Naud P, Chartier D, Qi XY, Comtois P, Fabritz L, Kirchhof P, Nattel S.

Cardiovasc Res. 2011 Oct 1;92(1):67-74. doi: 10.1093/cvr/cvr166. Epub 2011 Jun 14.

PMID:
21672931
48.

Load-reducing therapy prevents development of arrhythmogenic right ventricular cardiomyopathy in plakoglobin-deficient mice.

Fabritz L, Hoogendijk MG, Scicluna BP, van Amersfoorth SC, Fortmueller L, Wolf S, Laakmann S, Kreienkamp N, Piccini I, Breithardt G, Noppinger PR, Witt H, Ebnet K, Wichter T, Levkau B, Franke WW, Pieperhoff S, de Bakker JM, Coronel R, Kirchhof P.

J Am Coll Cardiol. 2011 Feb 8;57(6):740-50. doi: 10.1016/j.jacc.2010.09.046.

49.

PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression.

Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH, Rotering H, Fortmueller L, Laakmann S, Verheule S, Schotten U, Fabritz L, Brown NA.

Circ Cardiovasc Genet. 2011 Apr;4(2):123-33. doi: 10.1161/CIRCGENETICS.110.958058. Epub 2011 Jan 31.

PMID:
21282332
50.

Insights into sick sinus syndrome from an inducible mouse model.

Herrmann S, Fabritz L, Layh B, Kirchhof P, Ludwig A.

Cardiovasc Res. 2011 Apr 1;90(1):38-48. doi: 10.1093/cvr/cvq390. Epub 2010 Dec 30.

PMID:
21193513

Supplemental Content

Loading ...
Support Center